BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34478159)

  • 1. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
    Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.
    Zhao L; Wang Y; Tian T; Rao X; Dong W; Zhang J; Yang Y; Tao Q; Peng F; Shen C; Wang S; Liu H; Zeng X; Zhou W
    Hepatol Int; 2022 Dec; 16(6):1339-1352. PubMed ID: 36123506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis.
    Schäffer AA; Dominguez DA; Chapman LM; Gertz EM; Budhu A; Forgues M; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Wu X; Bayarsaikhan E; Harris CC; Ruchirawat M; Ruppin E; Wang XW
    BMC Genomics; 2021 Nov; 22(1):814. PubMed ID: 34763675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
    Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Ghaffari Laleh N; Zeng Q; Maille P; Favre L; Pujals A; Klein C; Bazille C; Heij LR; Uguen A; Luedde T; Di Tommaso L; Beaufrère A; Chatain A; Gastineau D; Nguyen CT; Nguyen-Canh H; Thi KN; Gnemmi V; Graham RP; Charlotte F; Wendum D; Vij M; Allende DS; Aucejo F; Diaz A; Rivière B; Herrero A; Evert K; Calvisi DF; Augustin J; Leow WQ; Leung HHW; Boleslawski E; Rela M; François A; Cha AW; Forner A; Reig M; Allaire M; Scatton O; Chatelain D; Boulagnon-Rombi C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Pawlotsky JM; Zhang X; Luciani A; Mulé S; Laurent A; Amaddeo G; Regnault H; De Martin E; Sempoux C; Navale P; Westerhoff M; Lo RC; Bednarsch J; Gouw A; Guettier C; Lequoy M; Harada K; Sripongpun P; Wetwittayaklang P; Loménie N; Tantipisit J; Kaewdech A; Shen J; Paradis V; Caruso S; Kather JN
    Nat Commun; 2023 Dec; 14(1):8290. PubMed ID: 38092727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
    Sasaki M; Sato Y; Nakanuma Y
    Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI for Hepatitis B-Associated Intrahepatic Cholangiocarcinoma: A Multicenter Comparative Study.
    Sheng R; Wang H; Zhang Y; Sun W; Jin K; Dai Y; Zhang W; Zeng M; Zhou J
    J Magn Reson Imaging; 2024 Mar; 59(3):1093-1104. PubMed ID: 37309823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
    Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
    Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
    Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
    Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
    Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas.
    Kikuchi AT; Umetsu S; Joseph N; Kakar S
    Am J Surg Pathol; 2023 Nov; 47(11):1207-1218. PubMed ID: 37661782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Sia D; Villanueva A; Friedman SL; Llovet JM
    Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.
    Jeon Y; Kwon SM; Rhee H; Yoo JE; Chung T; Woo HG; Park YN
    Hepatology; 2023 Jan; 77(1):92-108. PubMed ID: 35124821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.